Keyword: Juno Therapeutics
After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.
Novartis and Bayer executives were among a list of attendees at a private dinner in Davos with U.S. President Donald Trump.
Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
Juno Therapeutics has inked a deal to use Thermo Fisher Scientific’s activation reagents in manufacturing its CAR-T therapies.
Here is some other vaccine news of note for the week.
Novartis won crucial backing for its potentially groundbreaking CAR-T drug at an FDA expert panel on Wednesday.
How will Novartis price its CAR-T med if and when it wins an FDA nod? That's what the drugmaker is trying to figure out.
LONDON—Immuno-oncology drug developers have heard the debate about drug prices—and not only that. They’re listening.